CytomX Therapeutics (NASDAQ:CTMX) Stock Price Expected to Rise, Guggenheim Analyst Says

CytomX Therapeutics (NASDAQ:CTMX) had its price objective boosted by investment analysts at Guggenheim from $10.00 to $15.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price target suggests a potential upside of 175.23% from the stock’s previous close.

A number of other brokerages have also recently commented on CTMX. Cantor Fitzgerald raised their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Wedbush upped their price target on CytomX Therapeutics from $6.00 to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday. Barclays raised their price objective on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Piper Sandler lifted their price objective on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Finally, JPMorgan Chase & Co. upgraded CytomX Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $7.00 to $12.00 in a research note on Monday. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.13.

CytomX Therapeutics Trading Down 19.3%

Shares of CTMX stock opened at $5.45 on Wednesday. CytomX Therapeutics has a 12 month low of $0.40 and a 12 month high of $8.21. The stock has a market cap of $923.39 million, a P/E ratio of -136.25 and a beta of 2.44. The company has a 50 day simple moving average of $5.26 and a two-hundred day simple moving average of $4.09.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative return on equity of 20.65% and a negative net margin of 22.79%.The business had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $7.33 million. As a group, equities analysts forecast that CytomX Therapeutics will post -0.05 earnings per share for the current year.

Hedge Funds Weigh In On CytomX Therapeutics

Large investors have recently made changes to their positions in the business. Wells Fargo & Company MN lifted its position in shares of CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,000 shares in the last quarter. Farther Finance Advisors LLC purchased a new stake in shares of CytomX Therapeutics during the third quarter worth about $25,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of CytomX Therapeutics during the fourth quarter worth about $35,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in CytomX Therapeutics during the 3rd quarter valued at approximately $34,000. Finally, May Hill Capital LLC bought a new stake in CytomX Therapeutics during the 4th quarter valued at approximately $46,000. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

More CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Positive Phase I Varseta‑M (CX‑2051) data drove a surge in investor interest, showing dose‑dependent responses in late‑line colorectal cancer and underpinning recent upgrades and price‑target increases. CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
• Positive Sentiment: Several analysts raised ratings/targets after the clinical update — JPMorgan upgraded CTMX to overweight (higher conviction) and Wedbush raised its price target — providing buy‑side validation that upside remains tied to Varseta‑M progress. CytomX Therapeutics Stock Rating Upgraded by JPMorgan Chase & Co.
• Neutral Sentiment: HC Wainwright maintained a constructive view (Buy) and a high $17 price target while updating its models — the PT signals strong upside potential but relies heavily on successful Varseta‑M development. MarketBeat CTMX Coverage
• Negative Sentiment: CytomX priced an underwritten public offering to raise about $250M at $5.30 per share (and pre‑funded warrants), which dilutes existing shareholders and increases share overhang—a primary driver of the stock pullback. CytomX Announces Pricing of $250M Offering
• Negative Sentiment: Q4 results missed estimates: EPS and revenue came in below expectations, reinforcing near‑term financial pressure and validating analyst EPS downgrades. That miss amplified selling after the clinical‑driven rally. CTMX Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: HC Wainwright materially lowered EPS forecasts across 2026 quarters and cut FY2026 expectations (reflecting higher cash burn/near‑term losses), which can temper analyst confidence until clearer clinical or commercial milestones are reached. MarketBeat CTMX Coverage

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.